Evidence map›Paper›PMID 35290126›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2022

FMRP promotes transcription-coupled homologous recombination via facilitating TET1-mediated m5C RNA modification demethylation.

Haibo Yang, Yumin Wang, Yufei Xiang, Tribhuwan Yadav, Jian Ouyang, Laiyee Phoon, Xueping Zhu, Yi Shi, Lee Zou, Li Lan

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 1 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 1 synthesis or guideline pooled it, 187 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. The mClinical epigenetics · 2026
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Haibo YangMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129.ORCID 0000-0003-3038-6453
Yumin WangMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129.
Yufei XiangDepartment of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.ORCID 0000-0002-6732-5649
Tribhuwan YadavMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129.
Jian OuyangMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129.
Laiyee PhoonMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129.
Xueping ZhuCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Yi ShiDepartment of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.
Lee ZouMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129.
Li LanMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129.ORCID 0000-0003-0383-6172
Harvard University · USUniversity of Pittsburgh · US

Funding

Regulation of the ATR Checkpoint Kinase by DNA DamageR01GM076388 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI ZOU, LEE · 2006 to 2018
$4.3M
Implications of the ATR Checkpoint Kinase in Radiation and Targeted TherapiesR01CA197779 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI ZOU, LEE · 2015 to 2020
$2.4M
Transcription-Coupled Homologous Recombination upon DNA DamageR01GM118833 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LAN, LI · 2016 to 2020
$1.6M
Understanding and Targeting the R-Loop-Mediated DNA Damage Response at TelomeresR01CA282939 · NCI · DUKE UNIVERSITY · PI Li Lan · 2023 to 2026
$1.5M
NCI NIH HHS R01 CA197779NCI NIH HHS R01 CA282939NIGMS NIH HHS R01 GM076388NIGMS NIH HHS R01 GM118833
6 · The paper itself

Abstract

RNA modifications regulate a variety of cellular processes including DNA repair.The RNA methyltransferase TRDMT1 generates methyl-5-cytosine (m5C) on messen-ger RNA (mRNA) at DNA double-strand breaks (DSBs) in transcribed regions, pro-moting transcription-coupled homologous recombination (HR). Here, we identifiedthat Fragile X mental retardation protein (FMRP) promotes transcription-coupled HRvia its interaction with both the m5C writer TRDMT1 and the m5C eraser ten-eleventranslocation protein 1 (TET1). TRDMT1, FMRP, and TET1 function in a temporalorder at the transcriptionally active sites of DSBs. FMRP displays a higher affinity forDNA:RNA hybrids containing m5C-modified RNA than for hybrids without modifica-tion and facilitates demethylation of m5C by TET1 in vitro. Loss of either the chroma-tin- or RNA-binding domain of FMRP compromises demethylation of damage-inducedm5C in cells. Importantly, FMRP is required for R-loop resolving in cells. Due to unre-solved R-loop and m5C preventing completion of DSB repair, FMRP depletion or lowexpression leads to delayed repair of DSBs at transcriptionally active sites and sensitizescancer cells to radiation in a BRCA-independent manner. Together, ourfindings presentan m5C reader, FMRP, which acts as a coordinator between the m5C writer and eraserto promote mRNA-dependent repair and cell survival in cancer.

Indexed as

Fragile X Messenger Ribonucleoprotein 1Fragile X SyndromeCytosineDemethylationHomologous RecombinationHumansMixed Function OxygenasesProto-Oncogene ProteinsRNARNA, MessengerCytosineFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1Mixed Function OxygenasesProto-Oncogene ProteinsRNARNA, MessengerTET1 protein, humanDNA damage repairFMRPm5CmRNA modificationTRDMT1

Identifiers

PMID35290126
PMCPMC8944906
OpenAlexW4220651986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.